The short version of dihexa fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-28 and is reviewed periodically as new material appears.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
1,2-Diarylethylamines exert their primary effects as uncompetitive antagonists of the N-methyl-D-aspartate receptor (NMDAR), similar to phencyclidine (PCP) and ketamine. This mechanism is believed to underlie their characteristic dissociative, hallucinogenic, and anesthetic properties. Compounds such as diphenidine, methoxphenidine (MXP), and ephenidine display high to moderate affinity for the NMDAR PCP-binding site (e.g., diphenidine Ki ≈ 18–39 nM). Additionally, some members of this class exhibit secondary interactions with monoamine transporters, including the dopamine and norepinephrine transporters (DAT and NET), as well as modest binding to sigma-1 and sigma-2 receptors, serotonin 5-HT2A receptors, alpha-adrenergic receptors, and the kappa opioid receptor. Despite potent NMDAR binding, several compounds exhibit reduced in vivo potency, potentially due to pharmacokinetic factors.
== Study results == Eptifibatide was licensed due to the positive results of the so-called PURSUIT study encompassing 10,948 patients. In this study all patients had experienced either unstable angina or a non-ST-segment-elevation myocardial infarction. Significantly fewer patients developed a myocardial infarction under therapy with eptifibatide. Death rates showed a tendency in favor of eptifibatide, but this superiority was not statistically significant.
=== Extraction === Oil extraction is simply the removal of oil from the reservoir (oil pool). There are many methods of extracting the oil from the reservoirs for example; mechanical shaking, water-in-oil emulsion, and specialty chemicals called demulsifiers that separate the oil from water. Oil extraction is costly and often environmentally damaging. Offshore exploration and extraction of oil disturb the surrounding marine environment.
King Mendre, or the King of Persia (Polosi) or Anandavarma the kings of Tukhara (覩货罗, Tokharistan) had images painted in these caves for all the followers of the Buddha, by the artist and painter Mitradatta, also by Naravahanadatta, who came from a place of worship of the Niganthas, finally by Priyaratna who came from Syria (Rumakama, "Roman Empire") also with their apprentices. King Mendre and the King of Tukhara received the relics of Amitabha and went into the land of blessedness (Sukhavati). The son of the King of Tukhara called Dahuangfa (大黄发王) came to the city of Mir-li, preached the Kalachakra to all the Jaina-Niganthas and restored all the caves for the worship of Buddha. According to a recent translation by Sam van Schaik, the text should be:
In a nuclear reactor, such a chain reaction is slowed and controlled by a neutron poison, absorbing some of the free neutrons. Such neutron-absorbent materials are often part of reactor control rods (see nuclear reactor physics for a description of this process of reactor control). Other naturally occurring isotopes such as uranium-238 are fissionable, but not fissile, meaning that they only undergo fission when absorbing high energy (fast) neutrons. As little as 15 lb (6.8 kg) of uranium-235 can be used to make an atomic bomb. The nuclear weapon detonated over Hiroshima, Japan, named Little Boy, relied on uranium fission. However, the first nuclear bomb (the Gadget used at Trinity) and the bomb that was detonated over Nagasaki, Japan (Fat Man), were both plutonium bombs. Uranium metal has three allotropic forms:
Sources: en.wikipedia.org
== History == Behavioral endocrinology has roots in ethology and is also seen as a combination of endocrinology and psychology. Like ethology, behavioral endocrinology focuses on behavior on the level of the whole organism. The invention of radioimmunoassay techniques revolutionized behavioral endocrinology, allowing scientists to see and quantify hormones. The field historically resists reductionist thinking and focuses on the physiological aspects of behavior.
=== Dextran conjugate nanoparticles === Dextran conjugates are also utilized in nanoparticle drug delivery system formulations. Nanoparticles composted of dextran and stearic acid with a polyethylene glycol (PEG) coating can be loaded with antiviral drugs and be effectively internalized by cells. This nanosystem has the advantages of providing protection against immune responses and providing stability to the encapsulated drug. This technology has applications in the treatment of HIV and AIDS. Dextran can be grafted with folic acid to develop doxorubicin-loaded nanoparticles. Dextran-folic acid nanoparticles effectively target tumors, reduce off-site toxicity, and prolong blood circulation. Dextran-spermine nanoparticles loaded with doxorubicin can achieve targeted and sustained drug release in tumors.
The advantages of the demi-gaunt are that it allows better dexterity and is lighter than a full gauntlet, but the disadvantage is that the fingers are not as well protected. In a 2021-2022 archeological excavation a well-preserved and nearly-intact 14th-century gauntlet was discovered near Switzerland's Kyburg Castle.
=== Phase 1/2 === XC-101 (XC101; XC101-D13H) – serotonin 5-HT1B and 5-HT7 receptor agonist, serotonin 5-HT1D and 5-HT1F receptor partial agonist, and serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonist – migraine [29]
Sources: en.wikipedia.org
1993/1766) South Buckinghamshire National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1767) South Worcestershire Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1768) Commons Registration (Disposal of Disputed Registrations) (Amendment) Regulations 1993 (S.I. 1993/1771) Civil Defence (General Local Authority Functions) (Scotland) Regulations 1993 (S.I. 1993/1774) Education (Bursaries for Teacher Training) (Amendment) Regulations 1993 (S.I. 1993/1775) Gipsy Encampments (District of South Cambridgeshire) Order 1993 (S.I. 1993/1776) Local Government Finance Act 1992 (Recovery of Community Charge) Saving Order 1993 (S.I. 1993/1780) Consular Fees (Amendment) Order 1993 (S.I. 1993/1781) Continental Shelf (Designation of Areas) (No. 2) Order 1993 (S.I. 1993/1782) European Communities (Definition of Treaties) (Agreement on Customs Union and Co-operation between the European Economic Community and the Republic of San Marino) Order 1993 (S.I. 1993/1783) Haiti (United Nations Sanctions) Order 1993 (S.I. 1993/1784) Haiti (United Nations Sanctions) (Dependent Territories) Order 1993 (S.I. 1993/1785) Merchant Shipping Act 1979 (Overseas Territories) (Amendment) Order 1993 (S.I. 1993/1786) United Nations Arms Embargoes (Liberia, Somalia and the Former Yugoslavia) Order 1993 (S.I. 1993/1787) Appropriation (No. 2) (Northern Ireland) Order 1993 (S.I. 1993/1788) British Nationality (Hong Kong) (Selection Scheme) (Amendment) Order 1993 (S.I.
The New York State Agricultural Experiment Station recipe for the concentrate suggests starting with 80 lb of sulfur, 36 lb of quicklime, and 50 gal of water, equivalent to 19.172 kg of sulfur and 8.627 kg of calcium oxide per 100 liters of water. About 2.2:1 is the ratio (by weight) for compounding sulfur and quicklime; this ratio yields the highest proportion of calcium pentasulfide. If calcium hydroxide (builders' or hydrated lime) is used, an increase of one-third or more (to 115 g/L or more) may be used with the 192 g/L of sulfur. If the quicklime is 85%, 90%, or 95% pure, 101 g/L, 96 g/L, or 91 g/L is used, respectively; if impure hydrated lime is used, its quantity is increased to compensate, though in practice lime with a purity lower than 90% is rarely used. The mixture is then boiled for one hour while being stirred, and small amounts of water are added for evaporation.
=== Membrane-bound ribosomes === When a ribosome begins to synthesize proteins needed in certain organelles, the ribosome making this protein can become "membrane-bound". In eukaryotic cells this happens in a region of the endoplasmic reticulum (ER) called the "rough ER". The newly produced polypeptide chains are inserted directly into the ER by the ribosome undertaking vectorial synthesis and are then transported to their destinations, through the secretory pathway. Bound ribosomes usually produce proteins that are used within the plasma membrane or are expelled from the cell via exocytosis.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.